SCHEMBL2803185

SCHEMBL2803185

CCOC(=O)c1cnn2c(Nc3ccc4cc[nH]c4c3)c(C(=O)N3CCC(c4ccccc4)CC3)cnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 3/20 0.43
KDM4E B2RXH2 6/20 0.40
HSD17B10 Q99714 5/20 0.40
HPGD P15428 4/20 0.40
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
AVPR1A P37288 1/20 0.38
SYK P43405 1/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
MAPT P10636 1/20 0.38
HTR2B P41595 1/20 0.37
JAK2 O60674 1/20 0.37
JAK3 P52333 1/20 0.37
KDR P35968 1/20 0.37
PDE4B Q07343 3/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801496 0.95 SPR (0.43) SPRKDM4EHSD17B10HPGDALDH1A1
SCHEMBL2801644 0.90 SPR (0.44) SPRALDH1A1AVPR1ASYKPDE4B
SCHEMBL2802212 0.87 SPR (0.41) SPRALDH1A1AVPR1ASYKHTR2B
SCHEMBL2798539 0.87 SPR (0.44) SPRKDM4EHSD17B10HPGDALDH1A1
SCHEMBL2801492 0.86 SPR (0.45) SPRKDM4EHPGDALDH1A1NPC1
SCHEMBL2802820 0.86 ALDH1A1 (0.42) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL2800790 0.85 KDM4E (0.39) SPRKDM4EHSD17B10HPGDALDH1A1
SCHEMBL2800076 0.85 SPR (0.44) SPRALDH1A1NPC1RAB9AAVPR1A
SCHEMBL2801964 0.82 SPR (0.40) SPRALDH1A1AVPR1ASYKHTR2B
SCHEMBL2800432 0.81 KDM4E (0.41) KDM4EHSD17B10HPGDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 SPR 2955/4885KDM4E 3180/4885HSD17B10 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.